Alps Group

Alps Group Equity

The The Equity of Alps Group (ALPS) as of Oct 20, 2026 is -7.46 M USD. In the previous year, The Equity was 20.68 M USD — a change of -136.10% (lower).

Equity

-7.46 MUSD

YoY

-136.10%

Last updated:

In 2024, Alps Group's equity was -7.46 M USD, a -136.10% increase from the 20.68 M USD equity in the previous year.

The Alps Group Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2022
113.81 M USD
Jan 1, 2023
20.68 M USD
Jan 1, 2024
-7.46 M USD
The Alps Group Equity history
YEAREquityYoY
-7.46 MUSD-136.10%
20.68 MUSD-81.83%
113.81 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alps Group Stock analysis

What does Alps Group do? Alps Group Inc generates revenue through its integrated biotechnology platform Alps Life Sciences Inc., which offers advanced therapies and healthcare solutions. The company provides medical services, wellness solutions, and aesthetic treatments including non-surgical and surgical aesthetic services. Alps Life Sciences Inc. develops and commercializes therapies such as MyImmune (NK cells), CAR-T cells, and diabetes therapeutics, alongside research in mRNA vaccine technology and stem cell advancements like iPSCs. The firm operates molecular and cGMP laboratories for research and cultivation of cell and gene therapies. Alps Group Inc. targets global healthcare providers and patients seeking advanced medical solutions. Its biotechnology pipeline covers diverse areas including cancer therapies, infectious disease treatments, and regenerative medicine. The company's integrated ecosystem combines research, development, medical services, and wellness solutions to improve healthcare outcomes. The firm's aesthetic services cater to individuals seeking cosmetic and wellness procedures, while its medical services address broader healthcare needs. The company's revenue streams include the sale of medical services, wellness solutions, and aesthetic treatments. Alps Life Sciences Inc. focuses on developing therapies for specific health conditions such as diabetes and cancer, with a pipeline that includes mRNA-based vaccines and cell therapies. The molecular and cGMP laboratories support the development and production of these advanced therapies, contributing to the company's product offerings. Alps Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Alps Group's Equity

Alps Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Alps Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Alps Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Alps Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Alps Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Alps Group stock

The Equity of Alps Group is -7.46 M USD in 2024.

The Equity of Alps Group changed from 20.68 M USD to -7.46 M USD, representing a -136.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Alps Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Alps Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alps Group

All Key Metrics — Alps Group